LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Amgen Inc

Cerrado

SectorSanidad

290.17 1.13

Resumen

Variación precio

24h

Actual

Mínimo

289.48

Máximo

290.72

Métricas clave

By Trading Economics

Ingresos

1.1B

1.7B

Ventas

-937M

8.1B

P/B

Media del Sector

26.32

51.198

BPA

4.9

Rentabilidad por dividendo

3.3

Margen de beneficios

21.23

Empleados

28,000

EBITDA

-1.7B

1.2B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+12.35% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

3.30%

2.40%

Próximas Ganancias

5 ago 2025

Fecha Próximo Dividendo

5 sept 2025

Próxima Fecha de Ex Dividendo

15 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-3B

155B

Apertura anterior

289.04

Cierre anterior

290.17

Noticias sobre sentimiento de mercado

By Acuity

39%

61%

126 / 380 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Amgen Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

1 may 2025, 20:17 UTC

Ganancias

Amgen 1Q Revenue Up 9% as Many Products Deliver Double-Digit Sales Growth

28 may 2025, 18:09 UTC

Ganancias

Heart Disease Could Be a Goner When These New -2-

28 may 2025, 18:09 UTC

Ganancias

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

19 may 2025, 16:13 UTC

Adquisiciones, fusiones, absorciones

Regeneron Is Buying 23andMe. The Deal Is a Head Scratcher. -- Barrons.com

1 may 2025, 20:01 UTC

Ganancias

Amgen: FY25 Share Repurchases Not to Exceed $500M

1 may 2025, 20:01 UTC

Ganancias

Amgen: Guidance Includes Estimated Impact of Implemented Tariffs>AMGN

1 may 2025, 20:01 UTC

Ganancias

Amgen Sees FY25 Capital Expenditures About $2.3B

1 may 2025, 20:01 UTC

Ganancias

Amgen: Guidance Doesn't Account for Any Tariffs That Could Be Implemented in Future, Including Sector-specific Tariffs

1 may 2025, 20:01 UTC

Ganancias

Amgen 1Q Repatha Sales $656M >AMGN

1 may 2025, 20:01 UTC

Ganancias

Amgen 1Q EVENITY Sales $442M >AMGN

1 may 2025, 20:01 UTC

Ganancias

Amgen 1Q Worldwide Neulasta Sales $129M >AMGN

1 may 2025, 20:01 UTC

Ganancias

Amgen Sees FY25 Adj EPS $20-Adj EPS $21.20 >AMGN

1 may 2025, 20:01 UTC

Ganancias

Amgen 1Q Net $1.73B >AMGN

1 may 2025, 20:01 UTC

Ganancias

Amgen Sees FY25 EPS $12.21-EPS $13.46 >AMGN

1 may 2025, 20:01 UTC

Ganancias

Amgen 1Q Adj EPS $4.90 >AMGN

1 may 2025, 20:01 UTC

Ganancias

Amgen Sees FY25 Rev $34.3B-$35.7B >AMGN

1 may 2025, 20:01 UTC

Ganancias

Amgen 1Q Worldwide XGEVA Sales $566M >AMGN

1 may 2025, 20:01 UTC

Ganancias

Amgen 1Q Worldwide Prolia Sales $1.1B >AMGN

1 may 2025, 20:01 UTC

Ganancias

Amgen 1Q EPS $3.20 >AMGN

1 may 2025, 20:01 UTC

Ganancias

Amgen 1Q Worldwide Enbrel Sales $510M >AMGN

1 may 2025, 20:01 UTC

Ganancias

Amgen 1Q Rev $8.15B >AMGN

1 may 2025, 20:01 UTC

Ganancias

Amgen 1Q Worldwide Enbrel Sales $510M >AMGN

1 may 2025, 20:01 UTC

Ganancias

Amgen 1Q Rev $8.1B >AMGN

1 may 2025, 20:01 UTC

Ganancias

Amgen 1Q Net $1.73B >AMGN

1 may 2025, 20:01 UTC

Ganancias

Amgen 1Q Worldwide Neulasta Sales $129M >AMGN

1 may 2025, 20:01 UTC

Ganancias

Amgen Sees FY EPS $12.21-EPS $13.46 >AMGN

1 may 2025, 20:01 UTC

Ganancias

Amgen 1Q Worldwide Prolia Sales $1.1B >AMGN

1 may 2025, 20:01 UTC

Ganancias

Amgen 1Q Worldwide XGEVA Sales $566M >AMGN

1 may 2025, 20:01 UTC

Ganancias

Amgen 1Q EPS $3.20 >AMGN

1 may 2025, 20:01 UTC

Ganancias

Amgen Sees FY Adj EPS $20.00-Adj EPS $21.20 >AMGN

Comparación entre iguales

Cambio de precio

Amgen Inc previsión

Precio Objetivo

By TipRanks

12.35% repunte

Estimación a 12 Meses

Media 326.18 USD  12.35%

Máximo 400 USD

Mínimo 252 USD

De acuerdo con 22 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Amgen Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

22 ratings

11

Comprar

10

Mantener

1

Vender

Puntuación técnica

By Trading Central

270.44 / 276.44Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

126 / 380 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.